TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00541879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program ENERGY
Description: Weekly or biweekly classroom and gym based science enrichment focused on how the body works including blood glucose regulation, healthy eating and physical activity, diabetes abd how it can be prevented

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: comparison
Study: NCT04297319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser diiodo
Description: 3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks It is an outpatient procedure, not anesthesia required.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laser Placebo
Description: 3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks. It is an outpatient procedure, not anesthesia required.
Study: NCT02552732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHF with or without Oxygen
Description: NHF using myAIRVO™ 2 will be set at 25L/min at 37°C. However, all participants are able to lower the delivered temperature to 34°C.
Study: NCT03276078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide/Formoterol Fumarate 400/12μg BID
Description: Aclidinium bromide/formoterol fumarate 400/12μg administered by inhalation via the Genuair® multidose dry powder inhaler, twice daily (morning and evening) for 5 days
Study: NCT03226028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Patient is given an ipod with earphone and with saved playlists of different music genres. Music listening session will be given for 30 minutes before and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
Study: NCT00056394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Coping Skills Training
Description: 10 weekly, 80-minute coping skills treatment sessions, followed by a series of six biweekly follow-up telephone calls.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arthritis Education Sessions
Description: 10 weekly, 80-minute treatment sessions, followed by a series of six biweekly follow-up telephone calls. Participants will learn about the nature and treatment of rheumatoid arthritis as well as the benefits of exercise and joint protection.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Usual care from participants' rheumatologists but no treatment sessions.
Study: NCT01420471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Spacer will be impregnated with 2mL of Triamcinolone. The triamcinolone-impregnated spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 days following surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline-impregnated spacer
Description: Spacer will be impregnated with 2mL of Saline solution. The saline-impregnated spacer will be inserted into the middle meatal space intraoperatively. The spacer will be left in the middle meatus for a period of 6 days following surgery.
Study: NCT03086382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) tablet
Description: Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) tablet
Description: Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) syrup
Description: Treatment B: Single dose of Lacosamide (LCM) 200 mg given as syrup
Study: NCT03568097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 10 mg/kg will be given as intravenous infusion (IV) every two weeks (q 2 weeks) until disease progression.
Study: NCT03734315

Intervention type: DEVICE
Intervention: Ostenil®
Description: Ostenil® is a CE-certified viscoelastic solution for injection into the joint cavity, containing 1.0 % sodium hyaluronate from fermentation.
Study: NCT01563835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine, fentanyl
Description: 10mL of 0.125% of bupivacaine plus 50 mcg fentanyl, injected through an epidural catheter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: fentanyl IV PCA with boluses 25-50 mcg, 3-6 minute lockout.
Study: NCT00170664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT03437226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan 2.5 MG/ML
Description: Levosimendan Arm: 1 x 5 ml (1 vial) of levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Arm: 1 x 5 ml (1 vial) of placebo levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
Study: NCT03543436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temocillin
Description: Intravenous temocillin disodium 2g intravenously/8h Or Renally Adjusted Equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h) .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem or imipenem
Description: Intravenous carbapenem (meropenem 1g intravenously/8h Or Renally Adjusted Equivalent (ORAE) or imipenem 1g intravenously/8h ORAE)
Study: NCT03460392

Intervention type: DRUG
Intervention: Antibiotic therapy
Description: To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;

Intervention type: DRUG
Intervention: Antibiotic therapy
Description: To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;

Intervention type: DRUG
Intervention: Antibiotic therapy
Description: To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
Study: NCT03165838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postpartum Visit 3-4 Weeks
Description: This visit will be the same as the standard of care postpartum visit, but it will be scheduled earlier.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postpartum Visit 6-8 Weeks
Description: This standard of care postpartum visit will be scheduled for the standard time interval.
Study: NCT01026987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Infusion
Study: NCT03996135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cannulation with AccuVein AV400
Description: Cannulation using AccuVein AV400 device
Study: NCT02172235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone - low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 - low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 - medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 - medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 - medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 - high dose
Study: NCT02598856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal (IN) naloxone 1x
Description: Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
Study: NCT00801723

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo Tablet once daily.
Study: NCT04458441

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: warm group/cold group
Description: sequential randomization
Study: NCT00987441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine and sufentanil
Description: Ropivacaine 0.125% plus sufentanil 0.3 microgram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine and sufentanil
Description: Ropivacaine 0.125% plus sufentanil 0.4 microgram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine and sufentanil
Description: Ropivacaine 0.125% plus sufentanil 0.5 microgram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine and sufentanil
Description: Ropivacaine 0.0625% plus sufentanil 0.4 microgram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine and sufentanil
Description: Ropivacaine 0.1875% plus sufentanil 0.4 microgram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine and sufentanil
Description: Ropivacaine 0.25% plus sufentanil 0.4 microgram
Study: NCT02085486

Intervention type: OTHER
Group type: OTHER
Intervention: Standard
Description: Standard inspection, palpation.
Study: NCT02598856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal (IN) naloxone 1x
Description: Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
Study: NCT01675297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate/Cholecalciferol combination
Description: Risendronate/Cholecalciferol combination once a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Risedronate once a week
Study: NCT01511614

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation (tDCS), a type of Non-invasive Brain Stimulation (NIBS), has the potential to modify neuronal circuits by application of a subthreshold conductive current through the scalp. Two potential targets for tDCS as a smoking cessation aid are the dorsolateral pre-frontal cortex (dlPFC), a node of the ECN, and the ventromedial prefrontal cortex (vmPFC), a node of the DMN. tDCS can potentially strengthen the control of the ECN through excitatory stimulation of the dlPFC, and weaken the influence of the DMN (Lerman et al 2014) by inhibitory stimulation of the vmPFC. The tDCS model we will use is the neuroConn DC-Stimulator MR (neuroCare Group GmbH, Munchen, Germany).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: Sham Comparator
Study: NCT02672150

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Core
Study: NCT01511614

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine patch
Description: Dose-match Nicotine for non-deprived scan

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine patch
Description: Dose-match Nicotine for non-deprived scan

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo patch
Description: Nicotine deprived

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo patch
Description: Nicotine deprived

Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline Pill
Description: Treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo pill
Description: Active comparator to varenicline
Study: NCT01932970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Etelcalcetide is provided as a sterile lyophilized powder to be reconstituted with sterile water for injection.
Study: NCT02013700

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo
Description: The placebo will be 25 ml of Plasma-Lyte A with 1% HSA in a Cryostore bag.
Study: NCT02546531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Defactinib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Defactinib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT03053505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: faecal human microbiota transplant (FMT)
Description: Non-randomized group R: Patients with recurrent CD infection are treated with FMT in this group.~Randomized group FFMT: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with FMT.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: faecal human microbiota transplant (FMT)
Description: Non-randomized group R: Patients with recurrent CD infection are treated with FMT in this group.~Randomized group FFMT: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with FMT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin or Fidaxomicin
Description: Randomized group FAB: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with antibiotics (vancomycin per os 125mg four times a day for 10 days) in this group. In case of treatment failure changes in antibiotic regime (e.g. fidaxomicin per os 200mg per two times a day for 10 days) will be allowed in the line with the recommendations of current CDI treatment guidelines(13).
Study: NCT04389385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Specific T Cell derived exosomes (CSTC-Exo)
Description: The virus-specific T-cells (VSTs) are body's natural immune defense against various disease-causing viruses. Donor originated COVID-19 specific T-cells (CSTC) are in vitro activated and expanded by exposing to viral peptide fragments in the presence of natural immune stimulant proteins called cytokines. These Covid-19 specific fragment peptides activate specific T-cells and stimulate the secretion of potent mediators including IFN gamma in forms of exosomes. We propose treatment of Covid-19 patients -who are at early stages of pulmonary disease- with CSTC-exomes to control disease progression.
Study: NCT02672150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Study: NCT02598856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal (IN) naloxone 1x
Description: Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal (IN) naloxone 1x
Description: Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
Study: NCT02672150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced
Study: NCT02590406

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Beach chair (BC) and ZEEP
Description: Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg and NIPPV
Description: Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface
Study: NCT03200028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Description: Thirty minutes of training on computerized exercises that targets executive function, memory and attention.
Study: NCT01376908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan®
Description: Kuvan® (sapropterin dihydrochloride) tablets will be administered orally at the dose of 10 mg/kg/day and will be escalated to 20 mg/kg/day if after 4 weeks a subject's Phe tolerance is not increased by at least 20% versus baseline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phenylalanine (Phe)-restricted diet
Description: Phe intake will be adjusted every 2 weeks, based on the mean Phe levels of the previous 2 weeks using pre-defined Phe adjustment criteria.

Intervention type: OTHER
Group type: OTHER
Intervention: Phenylalanine (Phe)-restricted diet
Description: Phe intake will be adjusted every 2 weeks, based on the mean Phe levels of the previous 2 weeks using pre-defined Phe adjustment criteria.
Study: NCT00563381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium bromide
Description: 18 mcg/daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: 100 mcg/daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Salmeterol
Description: Placebo identical to Salmeterol device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tiotropium
Description: Placebo identical to Tiotropium device
Study: NCT01619774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: Starting dose 150 mg by mouth twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: 2 mg by mouth daily.
Study: NCT02688140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Study: NCT02289833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered intravenously (IV) at a dose of 3.6 mg/kg on Day 1 of every 21-day cycle until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the sponsor, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered intravenously (IV) at a dose of 3.6 mg/kg on Day 1 of every 21-day cycle until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the sponsor, whichever occurs first.
Study: NCT02598856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal (IN) naloxone 2
Description: Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal (IN) naloxone 2
Description: Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal (IN) naloxone 2
Description: Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal (IN) naloxone 2
Description: Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
Study: NCT01511614

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational Interviewing
Description: Motivational Interviewing for smoking cessation preparation
Study: NCT01436656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Study: NCT03403530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IgM rich Immunoglobin
Description: the 'IgM rich immunoglobn' is the normal human immunoglobin containing Human plasma protein 50mg/ml of which immunoglobin is atleast 95% Immunoglobin M (IgM) 6mg Immunoglobin A (IgA) 6mg Immunoglobin G (IgG) 38mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IgM rich Immunoglobin
Description: the 'IgM rich immunoglobn' is the normal human immunoglobin containing Human plasma protein 50mg/ml of which immunoglobin is atleast 95% Immunoglobin M (IgM) 6mg Immunoglobin A (IgA) 6mg Immunoglobin G (IgG) 38mg
Study: NCT01573286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon-Like Peptide 2
Description: Patients will be treated with 20 ug/kg/day GLP-2, in two doses, given subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued for a total of 42 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon like peptide-2
Description: Patients will treated with 5, 10 or 20 ug/kg/day of GLP-2, given twice daily by subcutaneous injection. The initial cohort of patients will be treated at 5 ug/kg (n=6), and if this dose is seen to be safe, and levels appropriate, the next group of 6 will be treated at 10 ug/kg/day. If this dose is seen to be safe, and levels appropriate, the final group of 6 will be treated at 20 ug/kg/day.~Patients will be given GLP-2 at the assigned dose, subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued, at the same dose, for a total of 42 days.
Study: NCT02446028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIOD-531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog® Mix 75/25
Study: NCT02180191

Intervention type: OTHER
Intervention: Comparison of the gut microbiota composition
Study: NCT02557776

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Germline genetic testing of BRCA1 and BRCA2
Study: NCT01934712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Single dose injected subcutaneously (s.c, under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faster-acting insulin aspart
Description: Single dose injected subcutaneously (s.c, under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Single dose injected subcutaneously (s.c, under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Single dose injected subcutaneously (s.c, under the skin)